In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was $12.87 for the day, up 4.29% from the previous closing price of $12.34. In other words, the price has increased by $4.29 from its previous closing price. On the day, 1.83 million shares were traded. ARWR stock price reached its highest trading level at $12.925 during the session, while it also had its lowest trading level at $12.24.
Ratios:
Our analysis of ARWR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.09 and its Current Ratio is at 6.09. In the meantime, Its Debt-to-Equity ratio is 16.58 whereas as Long-Term Debt/Eq ratio is at 16.43.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 11 ’25 when Anzalone Christopher Richard sold 50,800 shares for $11.49 per share. The transaction valued at 583,692 led to the insider holds 3,921,255 shares of the business.
Anzalone Christopher Richard sold 50,000 shares of ARWR for $543,500 on Apr 10 ’25. The Chief Executive Officer now owns 3,972,055 shares after completing the transaction at $10.87 per share. On Apr 09 ’25, another insider, Anzalone Christopher Richard, who serves as the Chief Executive Officer of the company, sold 40,322 shares for $10.07 each. As a result, the insider received 406,145 and left with 4,022,055 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 1767269632 and an Enterprise Value of 1947579648. For the stock, the TTM Price-to-Sale (P/S) ratio is 706.91 while its Price-to-Book (P/B) ratio in mrq is 30.73. Its current Enterprise Value per Revenue stands at 779.032 whereas that against EBITDA is -3.212.
Stock Price History:
The Beta on a monthly basis for ARWR is 0.91, which has changed by -0.42876166 over the last 52 weeks, in comparison to a change of 0.07455289 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $30.41, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of the stock is -20.22%, while the 200-Day Moving Average is calculated to be -37.60%.
Shares Statistics:
ARWR traded an average of 2.04M shares per day over the past three months and 2442370 shares per day over the past ten days. A total of 125.57M shares are outstanding, with a floating share count of 114.16M. Insiders hold about 16.87% of the company’s shares, while institutions hold 70.66% stake in the company. Shares short for ARWR as of 1743379200 were 11979733 with a Short Ratio of 5.86, compared to 1740700800 on 9196579. Therefore, it implies a Short% of Shares Outstanding of 11979733 and a Short% of Float of 11.2799995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
